EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Novacyt's Enterprise Value is €-38.87 Mil.
Novacyt's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-24.06 Mil. Therefore, Novacyt's EV-to-EBIT for today is 1.62.
The historical rank and industry rank for Novacyt's EV-to-EBIT or its related term are showing as below:
XPAR:ALNOV'
s EV-to-EBIT Range Over the Past 10 Years
Min: -217.31 Med: -3.71 Max: 10.57
Current: 1.61
During the past 12 years, the highest EV-to-EBIT of Novacyt was 10.57. The lowest was -217.31. And the median was -3.71.
XPAR:ALNOV's EV-to-EBIT is ranked better than 92.09% of 455
companies
in the Medical Devices & Instruments industry
Industry Median: 20.82
vs XPAR:ALNOV: 1.61
The historical data trend for Novacyt's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Novacyt's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novacyt's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Novacyt's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Novacyt's EV-to-EBIT falls into.
Novacyt's current Enterprise Value is €-38.87 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Novacyt's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-24.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novacyt (XPAR:ALNOV) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Novacyt's Enterprise Value for the quarter that ended in Jun. 2023 was €-64.88 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Novacyt's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-24.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novacyt EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Novacyt's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XPAR:ALNOV has been successfully added to your 